Definium's LSD-based pill meets Phase 3 goals in anxiety trial

September 14, 2026 7:01 AM

Definium Therapeutics (Nasdaq: DFTX) announced positive topline results from its Panorama Phase 3 trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found